Lantheus (NASDAQ:LNTH) Reports Upbeat Q2 CY2026

Radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 2.7% year on year to $388.2 million. Its non-GAAP profit of $1.55 per share was 18.9% above analysts’ consensus estimates.

Is now the time to buy Lantheus? Find out by accessing our full research report, it’s free.

Company Overview

Pioneering the "Find, Fight and Follow" approach to disease management, Lantheus Holdings (NASDAQGM:LNTH) develops and commercializes radiopharmaceuticals and other imaging agents that help healthcare professionals detect, diagnose, and treat diseases.

Revenue Growth

A company’s long-term sales performance is one signal of its overall quality. Any business can put up a good quarter or two, but the best consistently grow over the long haul. Thankfully, Lantheus’s 32.8% annualized revenue growth over the last five years was incredible. Its growth beat the average healthcare company and shows its offerings resonate with customers.

We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. Lantheus’s recent performance shows its demand has slowed significantly as its annualized revenue growth of 4% over the last two years was well below its five-year trend.

This quarter, Lantheus reported modest year-on-year revenue growth of 2.7% but beat Wall Street’s estimates by 7.8%.

Looking ahead, sell-side analysts expect revenue to decline by 3.2% over the next 12 months, a deceleration versus the last two years. This projection doesn’t excite us and indicates its products and services will face some demand challenges.

WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.

This is what the early days of Palantir looked like before it became a giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.

Adjusted Operating Margin

Adjusted operating margin is one of the best measures of profitability because it tells us how much money a company takes home after subtracting all core expenses, like marketing and R&D. It also removes various one-time costs to paint a better picture of normalized profits.

Lantheus’s adjusted operating margin has more or less stayed the same over the last 12 months , averaging 39.4% over the last five years. This profitability was elite for a healthcare business thanks to its efficient cost structure and economies of scale.

Looking at the trend in its profitability, Lantheus’s adjusted operating margin of 32.6% for the trailing 12 months may be around the same as five years ago, but it has decreased by 11.3 percentage points over the last two years.

This quarter, Lantheus generated an adjusted operating margin profit margin of 31%, down 9.4 percentage points year on year. This contraction shows it was less efficient because its expenses grew faster than its revenue.

Earnings Per Share

We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company’s growth is profitable.

Lantheus’s EPS grew at 85.6% compounded annual growth rate over the last five years, higher than its 32.8% annualized revenue growth. This tells us the company became more profitable on a per-share basis as it expanded.

In Q2, Lantheus reported adjusted EPS of $1.55, down from $1.57 in the same quarter last year. Despite falling year on year, this print easily cleared analysts’ estimates. Over the next 12 months, Wall Street expects Lantheus’s full-year EPS to shrink by 6.6% from $5.95 to $5.55.

Key Takeaways from Lantheus’s Q2 Results

We were impressed by how significantly Lantheus blew past analysts’ revenue expectations this quarter. We were also glad its EPS outperformed Wall Street’s estimates. Zooming out, we think this quarter featured some important positives. The stock remained flat at $101.93 immediately after reporting.

Lantheus put up rock-solid earnings, but one quarter doesn’t necessarily make the stock a buy. Let’s see if this is a good investment. When making that decision, it’s important to consider its valuation, business qualities, as well as what has happened in the latest quarter. We cover that in our actionable full research report which you can read here (it’s free).